Meeting
2023 ASCO Annual Meeting
Neoadjuvant chemoimmunotherapy for the treatment of locally advanced laryngeal and hypopharyngeal squamous cell carcinoma: A single-arm phase 2 clinical trial.
Authors
Yanfeng Chen
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Yanfeng Chen , Ankui Yang , Yan-Ping Mao
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Local-Regional Disease
Clinical Trial Registration Number
ChiCTR2000033506
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 6077)
DOI
10.1200/JCO.2023.41.16_suppl.6077
Abstract #
6077
Poster Bd #
69
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Tislelizumab plus chemotherapy as induction treatment followed by chemoradiotherapy or surgery in locally advanced hypopharyngeal squamous cell carcinoma: A single-arm, phase II trial.
First Author: Lin Gui
Poster
2024 ASCO Annual Meeting
Neoadjuvant immunochemotherapy for locally advanced hypopharyngeal squamous cell carcinoma: Pooled results analysis from two prospective single-arm phase 2 trials.
First Author: Lin Gui
Poster
2024 ASCO Genitourinary Cancers Symposium
First results of NURE-Combo: A phase 2 study of neoadjuvant nivolumab (NIVO) and nab-paclitaxel (ABX) followed by postsurgical adjuvant NIVO in patients (pts) with muscle-invasive bladder cancer (MIBC).
First Author: Chiara Mercinelli
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Safety and efficacy of neoadjuvant docetaxel, cisplatin, and 5-fluorouracil (Neo DCF) therapy for locally advanced esophageal cancer: Real world data analysis.
First Author: Mikako Tamba